← All Avidity Biosciences, INC filings

Avidity Biosciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
RNA
Avidity Biosciences, INC
10-K: Avidity Biosciences 2025 Annual Report: Novartis Merger & Clinical Progress
Avidity Biosciences reports significant clinical advancements for its AOC pipeline, including positive del-zota data and FDA designations, alongside a pending merger with Novartis AG and a spin-off of its early-stage cardiology programs.
NASDAQ
RNA
Avidity Biosciences, INC
10-K: Avidity Biosciences Reports Positive Data and Outlines 2025 Milestones in Annual 10-K Filing
Avidity Biosciences highlights positive clinical data across its DM1, FSHD, and DMD programs and anticipates a BLA submission for del-zota in DMD44 by year-end 2025.
NASDAQ
RNA
Avidity Biosciences, INC
10-K: Avidity Biosciences Secures \$40 Million Investment from Bristol Myers Squibb in Expanded Collaboration
Avidity Biosciences has entered into a strategic collaboration with Bristol Myers Squibb, including a \$40 million equity investment, to advance cardiovascular therapeutics using its AOC platform.